Market Overview
The market size for treatments for chronic lymphocytic leukaemia was estimated at USD 4.9 billion in 2023. The market for treating chronic lymphocytic leukaemia is anticipated to increase from USD 5.3 billion in 2023 to USD 8.68 billion in 2030, with a compound annual growth rate (CAGR) of 8.52% over the five-year forecast period (2023–2030). greater leukaemia incidence, a sizable unmet medical need for cancer therapy, hereditary blood abnormalities, and greater investment in the healthcare industry are the main major factors boosting the market share of chronic lymphocytic leukaemia treatments.
Market Trends
The growing prevalence of chronic lymphocytic leukemia drives the market growth
Chronic lymphocytic leukemia (CLL) is a cancer affecting the white blood cells. Radiation therapy, chemotherapy, and stem cell transplants are possible treatments for CLL. CLL treatment is essential because it can help improve symptoms and increase life expectancy. In India, there are one million new cases of chronic lymphocytic leukemia diagnosed every year, according to an article written by Apollo Hospitals. According to cancer statistics, one in 155 men and one in 260 women in England suffer from chronic lymphocytic leukaemia. Leukemia affects a large part of the world's population. Leukemia is diagnosed by acute and chronic illnesses caused by exposure to radiation, poor lifestyle choices and environmental factors. According to the 2021 Leukemia& Lymphoma Society study, men are affected by leukemia at a rate of approximately 36.5%. Men are diagnosed with and die of leukemia more often than women. Additionally, leukemia affected people of all genders and ages, with 474,519 cases worldwide in 2020, according to GLOBOCAN 2021 statistics. According to the same source, leukemia was one of the leading causes of death in the world in 2020. As a result, global data indicates that a significant population is susceptible to leukemia, which could positively impact the growth of chronic lymphocytic leukemia CAGR. processing market over the projection period. .
The market is expected to be impacted by the growth of the biotechnology sector, advancements in medication discovery, and increased R&D spending. As an illustration, to hasten the development of newer and more effective immunotherapies for the treatment of blood malignancies, the Leukaemia & Lymphoma Society's Therapy Acceleration Programme announced five new investments in April 2021. As a consequence of R&D and the launch of new products by a number of firms, the market is anticipated to expand.For instance, the National Cancer Institute (NCI) and Mayo Clinic will team up on a Phase I study on September 22, 2023, to evaluate the safety, effectiveness, and ideal dose of Onvansertib for the treatment of persons with leukaemia. either non-responsive or prone to relapse. The PLK1 enzyme is bound to by onvansertib and inhibited, which stunts the development of cancer cells and harms healthy cells. As a consequence of product development activities and product launches, the market revenue for therapeutics for chronic lymphocytic leukaemia is rising.
Segment Insights
Based on types, chronic lymphocytic leukemia treatment market segmentation includes indolent, aggressive and others. The indolent segment held the majority share in 2023, contributing around 65-67% of chronic lymphocytic leukemia treatment market revenue. The growth of the indolent segment of the chronic lymphocytic leukemia treatment market is mainly driven by the increase in the incidence of comorbidities, especially in the elderly, and the introduction of new drugs in development. Indolent chronic lymphocytic leukemia grows slowly and can remain stable for years without treatment. If the chronic lymphocytic leukemia is indolent, the blood count of other blood cells is average or slightly below average, even if more lymphocytes are present. With approximately 20,000 new cases expected to be diagnosed in 2023, Chinese society is aware of chronic lymphocytic leukemia. This indolent B-cell malignancy is the most common adult leukemia in the United States.
Treatment Insights
Treatments has divided chronic lymphocytic leukemia treatment market data into Chemotherapy, Targeted Drug Therapy, Immunotherapy, and Bone Marrow Transplantation. Chemotherapy segment dominated the market in 2023 and is expected to be the fastest growing segment during the forecast period 2023-2030. Chemotherapy is the first-line treatment for patients with chronic lymphocytic leukemia. It works by destroying cancer cells or reducing their growth rate. Standard chemotherapies include Dacogen (RAD-24), Cytarabine (Ablation), Fludara, fluorouracil, hydroxyurea, and procarbazine. Additionally, stem cell transplants can be used with chemotherapy, allowing healthcare providers to induce high-dose chemotherapy transfusions for effective treatment. Several companies are focusing on developing breakthrough drugs for the treatment of chronic lymphocytic leukemia in order to maintain their competitive edge and enter new regional markets. As a result, chemotherapy is the primary mode of treatment for most leukemia patients, thereby driving the growth of the segment market.
Furthermore, throughout the projection period, targeted medication therapy is the fastest-growing category in the chronic lymphocytic leukaemia treatment business. This therapy provides benefits over chemotherapy in terms of accuracy, therapeutic efficiency, and recovery time. Furthermore, targeted pharmacological treatments are becoming more common for treating this kind of chronic lymphocytic leukaemia.
End User Insights
Based on end user, the chronic lymphocytic leukaemia therapy market has been segmented into hospitals and specialty clinics. Hospitals had the biggest sector share in 2023. Many hospitals worldwide are using cutting-edge treatments and equipment to treat chronic lymphocytic leukaemia. Stem cell transplantation is the principal therapeutic strategy for rare cases of leukaemia that occur only in hospital settings across the world. According to an article released by Apollo Hospitals, around 1 million cases of chronic lymphocytic leukaemia are diagnosed in India each year. According to cancer statistics, 1 in 155 men and 1 in 260 women in England will develop chronic lymphocytic leukaemia over their lifetime. A spike in the number of cancer patients is propelling the industry forward.
Regional Analysis
By Region, the study provides market insights across North America, Europe, Asia-Pacific, and Rest of the World. The North America chronic lymphocytic leukemia treatment market was worth USD 2.24 billion in 2023 and is expected to exhibit significant growth in CAGR during the study period. The availability of well-established medical facilities, high awareness of early diagnosis, and experimental and advanced therapies contribute to its large revenue share. Additionally, the growing prevalence of chronic lymphocytic leukemia and increase in government funding is expected to expand the regional chronic lymphocytic leukemia treatment industry during the projection period. The United States is leading the chronic lymphocytic leukemia treatment market due to high healthcare expenditure, R&D activities and increasing prevalence of leukemia. According to updated 2023 data from the American Cancer Society, nearly 60,650 new cases of leukemia (all types combined) are expected to be diagnosed in 2023, with chronic lymphocytic leukemia treatment accounting for about 20,160 new cases.
Further, the major countries studied in the market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil.
The European chronic lymphocytic leukemia treatment market accounts for the second largest market share due to growing adult population and increasing R&D activities aimed at chronic lymphocytic leukemia treatment in the region. Recently, the European government announced the launch of a program called the European Cancer Plan, which promises to provide high-quality screening treatment and has set strategic goals such as disease control, early detection , diagnosis and treatment, as well as improving the quality of life for cancer patients. According to Cancer Research UK, approximately 3,800 new cases of chronic lymphocytic leukemia are diagnosed each year in the UK. Thus, it is expected that the increasing incidence of chronic lymphocytic leukemia will also increase the demand for drugs to treat the disease in Europe. In addition, the German chronic lymphocytic leukemia treatment market held the largest share of market revenue, and the French chronic lymphocytic leukemia treatment market was the fastest growing market in the European region.
Asia Pacific chronic lymphocytic leukemia treatment market is expected to grow at the fastest CAGR from 2023 to 2030 owing to high unmet clinical need, increasing disposable income, accessibility to effective treatment and growing awareness of early diagnosis in emerging countries such as China and India. This regional chronic lymphocytic leukemia treatment market has grown further owing to the increase in research in regenerative medicine for the treatment of leukemia and the growing awareness of personalized medicine. Additionally, China chronic lymphocytic leukemia treatment market held the largest market share, and India chronic lymphocytic leukemia treatment market was the fastest growing market in the Asia-Pacific region.
Competitive Landscape
The chronic lymphocytic leukemia treatment industry is moderately consolidated, with several major players. Major market players are developing biosimilars to existing chemotherapies, and other companies are launching generic products that are becoming increasingly common in the industry. Furthermore, market players are launching new treatments, entering into contracts, acquiring companies, concluding licensing agreements, increasing R&D investments and working with other organizations, among other key market developments, to expand their imprint.
In recent years, the chronic lymphocytic leukemia treatment industry has brought essential benefits to personalized medicine. Major players in the chronic lymphocytic leukemia treatment market including GlaxoSmithKline Plc, Teva Pharmaceutical Industries Ltd, Novartis AG, AstraZeneca and others are striving to augment the market demand by funding research and development initiatives of kind of treatment.
Atara Biotherapeutics Inc is a biopharmaceutical company focused on T-cell immunotherapy. Atara Biotherapeutics Inc creates therapies for patients with solid tumors, hematologic tumors and autoimmune diseases in the United States. In December 2020, Atara Biotherapeutics and Bayer AG announced a partnership to create mesothelin-targeted CAR T-cell therapies for solid tumors in the chronic lymphocytic leukemia treatment industry. This partnership has advanced the company's ATA2271 R&D, enabling it to become the largest manufacturer of allogeneic CAR-T stem cell transplants.
Additionally, Seagen Inc is a US-based biotechnology company focused on the development and commercialization of innovative and competent monoclonal antibody-based cancer therapies. Seagen and Merck announced a collaboration for two new strategic studies for the treatment of chronic lymphocytic leukemia in September 2020. The collaboration runs an extensive joint development program in various cancers. KEYTRUDA is approved as adjuvant therapy for patients with melanoma with lymph node involvement after complete resection.
Key Companies in the chronic lymphocytic leukemia treatment market include
- Hoffmann-La Roche Ltd
- GlaxoSmithKline Plc
- Genmab A/S
- Teva Pharmaceutical Industries Ltd
- Genentech Inc
- Genzyme Corporation
- AbbVie Inc
- Gilead
- Novartis AG
- Johnson & Johnson Services Inc
- AstraZeneca
- TG Therapeutics Inc
- Ziopharm Oncology Inc
Chronic Lymphocytic Leukemia Treatment Industry Developments
August 2023 AstraZeneca received FDA approval for a tablet version of the drug Calquence for the chronic lymphocytic leukemia treatment (CCL), small lymphocytic leukemia (SLL), and treated effectively relapsed or refractory Mantle Cell Lymphoma (MCL).
May 2019 AbbVie Inc received FDA approval for Venclexta in combined application with Gazyva for chronic lymphocytic leukemia treatment.
January 2019 Imbruvica, in combination with obinutuzumab, has been approved by the FDA for treating patients with chronic lymphocytic leukemia by Janssen Services LLC.
Chronic Lymphocytic Leukemia Treatment Market Segmentation
Chronic Lymphocytic Leukemia Treatment Type Outlook
- Indolent
- Aggressive
- Others
Chronic Lymphocytic Leukemia Treatment Outlook
- Chemotherapy
- Targeted Drug Therapy
- Immunotherapy & Bone Marrow Transplant
Chronic Lymphocytic Leukemia Treatment End User Outlook
- Hospitals
- Specialty Clinics
Chronic Lymphocytic Leukemia Treatment Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America